{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-043729","form_type":"8-K","ticker":"BNGO","cik":"0001411690","company_name":"Bionano Genomics, Inc.","filed_at":"2022-11-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.520770+00:00","generated_at":"2026-06-21T11:36:13.623001+00:00","sec_items":["2.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bionano completes acquisition of Purigen Biosystems for $32M cash, plus $32M earnout","bullets":["Closed acquisition of Purigen Biosystems on Nov 30, 2022; upfront cash consideration ~$32M.","Up to additional $32M in cash payable upon achievement of certain milestones.","Purigen survives as a wholly owned subsidiary of Bionano Genomics.","Consideration subject to customary adjustments for cash, debt, transaction expenses, and net working capital.","Post-closing purchase price adjustment mechanism with escrow for potential adjustments."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-043729","json":"https://secwatch.observer/filing/0001140361-22-043729.json","markdown":"https://secwatch.observer/filing/0001140361-22-043729.md","text":"https://secwatch.observer/filing/0001140361-22-043729.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/0001140361-22-043729-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/brhc10044882_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:36:13.623001+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"07275a76739882ca3ea651d8153c88aa873211aa","claim":"Bionano Genomics, Inc. completed an acquisition involving Purigen Biosystems, Inc. for approximately $32.0 million in cash (closed 2022-11-30).","evidence_excerpt":"the surviving corporation of the Merger and a wholly owned subsidiary of the Company. Pursuant to the Merger, the Company paid at closing upfront consideration of approximately $32.0 million in cash. The upfront consideration was subject to adjustment for, among other things, cash, unpaid indebtedness, unpaid transaction expenses and net working capital relative to","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411690/000114036122043729/0001140361-22-043729-index.htm","confidence":1.0,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Purigen Biosystems, Inc."},{"label":"Consideration","value":"approximately $32.0 million in cash"},{"label":"Closing","value":"2022-11-30"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}